Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Nov
12
Today In Oncology
CTCL Denileukin Diftitox May Improve HRQoL
Researchers Pinpoint Hundreds of Genetic Variants That May Offer New Insights Into Inherited Breast Cancer Risk
Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer
KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
FDA Approves Pimicotinib for Symptomatic TGCT
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo